MDCO

The Medicines Company Press Releases

$23.34
*  
0.69
3.05%
Get MDCO Alerts
*Delayed - data as of Oct. 21, 2014  -  Find a broker to begin trading MDCO now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
ORBACTIVTM (Oritavancin) Phase 3 SOLO II Trial Results Published in the Journal Clinical Infectious Diseases
10/9/2014 4:53:00 PM - Business Wire
▲8.91 % Price Change since this news event. The Volume Ratio is 1.31.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


The Medicines Company to Announce Third Quarter 2014 Financial Results on Wednesday, October 22, 2014
10/8/2014 7:20:00 PM - Business Wire


The Medicines Company to Announce Third Quarter 2014 Financial Results on Wednesday, October 22, 2014
10/8/2014 7:20:00 PM - Business Wire
▲8.91 % Price Change since this news event. The Volume Ratio is 0.99.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


The Medicines Company Infectious Disease Portfolio Data to Be Presented at ID Week 2014
10/6/2014 2:22:00 PM - Business Wire


The Medicines Company to Webcast Infectious Disease Care Investor & Analyst Day on September 24
9/23/2014 7:00:00 PM - Business Wire


Frazier Healthcare Appoints David Socks as Venture Partner, Establishes Boston Presence
9/19/2014 8:00:00 AM - Business Wire


The Medicines Company to Review ORBACTIVTM (oritavancin) Launch Readiness on Tuesday, September 16, 2014
9/12/2014 11:30:00 AM - Business Wire


The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
8/27/2014 1:12:00 PM - Business Wire


The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast “ALN-PCSsc for the Treatment of Hypercholesterolemia”
8/7/2014 9:42:00 AM - Business Wire


FDA Approves The Medicines Company's ORBACTIV™ (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections
8/6/2014 8:31:00 PM - Business Wire


The Medicines Company to Host Infectious Disease Care Investor and Analyst Meeting on September 24, 2014
8/4/2014 8:33:00 AM - Business Wire